In other studies, for HR-positive and HER-2 negative, HR-negative and HER-2 negative, and HR-negative and HER-2 positive breast cancers the rates of ALN negativity after NAC were approximately 20%, 50%, and 60% to 90%, respectively, which are generally in line with the present findings (12). This evidence concerns the gene ARLN and breast carcinoma.